Prospective observational evaluation of the particle immunofiltration anti-platelet factor 4 rapid assay in MICU patients with thrombocytopenia

Critical Care

Daniel H Kett¹  Daniel L Seckinger²  Sartia K Paulino²  G Fernando Cubillos¹  David M Andrews² 

[1] Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine at the University of Miami Miller School of Medicine and Jackson Memorial Hospital, 1611 NW 12th Avenue, Room C455A, Miami, FL 33136, USA;Department of Pathology and Laboratory Medicine at the University of Miami Miller School of Medicine and Jackson Memorial Hospital, Holtz Building, Room 2026, 1611 NW 12th Avenue, Miami, FL 33136, USA

关键词: clinical laboratory techniques;    thrombosis;    intensive care;    platelet factor 4;    thrombocytopenia;    heparin;   

Others  :  818017
DOI  :  10.1186/cc12822

 received in 2013-02-22, accepted in 2013-07-22,  发布年份 2013

【 摘 要 】

Introduction

Heparin-induced thrombocytopenia (HIT) results from antibodies to PF4/heparin complexes and clinical diagnosis is difficult. We evaluated the particle immunofiltration anti-platelet factor 4 (PIFA) rapid assay, in conjunction with a clinical risk score, in the diagnosis of HIT.

Methods

We performed a prospective observational study in all patients admitted to the medical intensive care unit (MICU) in a large academic medical center. Patients were screened daily for thrombocytopenia defined as either a platelet count that decreased by at least 33% or an absolute platelet count less than 150,000/μL. Patients with suspected HIT underwent PIFA and ELISA testing for anti-PF4/heparin antibodies. Available residual frozen sera were sent to a reference laboratory for serotonin release assay (SRA) testing.

Results

During the study period, 340 patients were admitted to the MICU, of which 143 patients met criteria for thrombocytopenia. Forty-three patients had no evidence of recent heparin exposure. PIFA and ELISA testing were performed on 100 patients, of which 92 had samples available for SRA analysis. PIFA results were negative in 62, positive in 28 and inconclusive in 2 patients. The 4Ts score showed low to intermediate risk in 57 of the PIFA negative patients. The ELISA results were negative in 86 and positive in 6 patients. SRA testing identified 3 patients with a positive SRA test and 89 patients with a negative result. All patients with a negative PIFA result also had a negative SRA result. In the one patient deemed to have clinical HIT, the pretest probability was high (4Ts score of 6) and the anti-PF4/heparin antibody testing revealed a positive SRA, inconclusive PIFA and a negative ELISA result.

Conclusions

While thrombocytopenia in our population is common, the prevalence of HIT is low. The combination of a low to intermediate pretest probability with a negative PIFA test can rapidly exclude the presence of platelet activating anti-PF4/heparin antibodies and, therefore, HIT as the cause of the thrombocytopenia. Since a positive PIFA result has a low positive predictive value, a positive PIFA is not diagnostic of HIT and additional evaluation is warranted.

【 授权许可】

   
2013 Andrews et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Crespo EM, Oliveira GB, Honeycutt EF, Becker RC, Berger PB, Moliterno DJ, Anstrom KJ, Abrams CS, Kleiman NS, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Granger CB, Ohman EM, CATCH Registry Investigators: Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: the Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. Am Heart J 2009, 157:651-657.
• [2]Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
• [3]Linkins L-A, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M, American College of Chest Physicians: Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 Suppl):e495S-530S.
• [4]Akca S, Haji-Michael P, de Mendonca A, Suter P, Levi M, Vincent JL: Time course of platelet counts in critically ill patients. Crit Care Med 2002, 30:753-756.
• [5]Crowther MA, Cook DJ, Meade MO, Griffith LE, Guyatt GH, Arnold DM, Rabbat CG, Geerts WH, Warkentin TE: Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 2005, 20:348-353.
• [6]Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG: Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002, 30:1765-1771.
• [7]Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A: Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006, 4:759-765.
• [8]Crowther MA, Cook DJ, Albert M, Williamson D, Meade M, Granton J, Skrobik Y, Langevin S, Mehta S, Hebert P, Guyatt GH, Geerts W, Rabbat C, Douketis J, Zytaruk N, Sheppard J, Greinacher A, Warkentin TE, Canadian Critical Care Trials Group: The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 2010, 25:287-293.
• [9]Khan MM, Noble DW, Watson HG: Heparin-induced thrombocytopenia and the utility of the 4Ts score in the intensive care unit. Br J Haematol 2011, 152:672-674.
• [10]GEN-PROBE LIFECODES® PF4 Enhanced assay package insert [http://www.gen-probe.com/pdfs/pi/303288_PF4Enhanced.IFUEN_2012-06-08.pdf] webciteWaukesha, WI: Gen-Probe GTI Diagnostics; 2012.
• [11]ASSERACHROM® HPIA [http:/ / www.stago-us.com/ products-services/ catalog/ reagents/ product-sheets/ selection/ type-reagents/ reference/ asserachrom-hpia-elisa/ ] webciteParsippany, NJ: Diagnostica Stago Inc; 2011.
• [12]PIFA® Heparin/PF4 Rapid Assay package insert [http:/ / www.akersbiosciences.com/ products/ us/ heparin/ documents/ 1-2011_PIFA_HPF4_pn_1322003_r5.pdf] webciteThorofare, NJ: Akers Biosciences, Inc; 2011.
• [13]Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG: Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008, 6:1304-1312.
• [14]Lo GK, Sigouin CS, Warkentin TE: What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007, 82:1037-1043.
• [15]Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA: Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004, 2:2133-2137.
• [16]Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, Eichler P, Warkentin TE: Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007, 5:1666-1673.
• [17]Alpert D, Mandl LA, Erkan D, Yin W, Peerschke EI, Salmon JE: Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis 2008, 67:395-401.
• [18]Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003, 76:2121-2131.
• [19]Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG: Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003, 23:745-753.
• [20]Levine RL, Hergenroeder GW, Francis JL, Miller CC, Hursting MJ: Heparin-platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study. J Thromb Thrombolysis 2010, 30:142-148.
• [21]Krauel K, Potschke C, Weber C, Kessler W, Furll B, Ittermann T, Maier S, Hammerschmidt S, Broker BM, Greinacher A: Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011, 117:1370-1378. [Erratum appears in Blood 2011, 117:5783]
• [22]Hursting MJ, Pai PJ, McCracken JE, Hwang F, Suvarna S, Lokhnygina Y, Bandarenko N, Arepally GM: Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol 2010, 134:774-780.
• [23]Greinacher A, Holtfreter B, Krauel K, Gatke D, Weber C, Ittermann T, Hammerschmidt S, Kocher T: Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011, 118:1395-1401.
• [24]Wilke T, Tesch S, Scholz A, Kohlmann T, Greinacher A: The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis. J Thromb Haemost 2009, 7:766-773.
• [25]Smythe MA, Koerber JM, Fitzgerald M, Mattson JC: The financial impact of heparin-induced thrombocytopenia. Chest 2008, 134:568-573.
• [26]Boyce SW, Bandyk DF, Bartholomew JR, Frame JN, Rice L: A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study. Am J Ther 2011, 18:14-22.
• [27]Smythe MA, Koerber JM, Forsyth LL, Priziola JL, Balasubramaniam M, Mattson JC: Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients. Pharmacotherapy 2009, 29:1073-1081.
• [28]Kiser TH, Fish DN: Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006, 26:452-460.
• [29]Wester JP, Leyte A, Oudemans-van Straaten HM, Bosman RJ, van der Spoel JI, Haak EA, Porcelijn L, Zandstra DF: Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill. Neth J Med 2007, 65:101-108.
• [30]Wells PS, Owen C, Doucette S, Fergusson D, Tran H: Does this patient have deep vein thrombosis? JAMA 2006, 295:199-207.
• [31]Wells PS, Anderson DR, Rodger M, Stiell I, Dreyer JF, Barnes D, Forgie M, Kovacs G, Ward J, Kovacs MJ: Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and D-dimer. Ann Intern Med 2001, 135:98-107.
• [32]Shelat SG, Tomaski A, Pollak ES: Serologic results in >1000 patients with suspected heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2008, 14:410-414.
• [33]Prechel MM, McDonald MK, Jeske WP, Messmore HL, Walenga JM: Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J Thromb Haemost 2005, 3:2168-2175.